AbbVie ABBV has built a substantial neuroscience franchise. While the segment was initially anchored by Botox Therapeutic and the depression drug Vraylar, its offerings now include the oral migraine ...

A number of pivotal announcements this year – including Neuralink’s first brain implant trial, and major funding rounds from companies such as Motif Neurotech with its miniaturized neurostimulator for ...

Over the past few years, AbbVie’s ABBV neuroscience franchise has shifted from a secondary portfolio to a meaningful growth engine. The segment has consistently delivered double-digit growth, with its ...

Long-term investors shouldn't overlook this top pharma stock and top medical device maker. AbbVie is seeing impressive growth from both its immunology portfolio and neuroscience products. Medtronic is ...